866-997-4948(US-Canada Toll Free)

Chemotherapy Induced Anemia - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Aug 2017

Category :

Pharmaceutical

No. of Pages : 50 Pages

Chemotherapy Induced Anemia - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Anemia - Pipeline Review, H2 2017, provides an overview of the Chemotherapy Induced Anemia (Toxicology) pipeline landscape.

Chemotherapy-induced anemia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness, cognitive impairment, loss of sexual desire, inability to perform daily functions and/or depression associated with anemia. The predisposing factors include age, co-morbidities, time course of therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Anemia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Anemia (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Anemia (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1, 2 and 4 respectively.

Chemotherapy Induced Anemia (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Anemia (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Anemia (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chemotherapy Induced Anemia (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chemotherapy Induced Anemia (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Anemia (Toxicology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Anemia (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Anemia (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chemotherapy Induced Anemia - Overview
Chemotherapy Induced Anemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Chemotherapy Induced Anemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chemotherapy Induced Anemia - Companies Involved in Therapeutics Development
3SBio Inc
Chong Kun Dang Pharmaceutical Corp
Galenica Ltd
Novartis AG
Panacea Biotec Ltd
Pfizer Inc
PharmaEssentia Corp
PhytoHealth Corp
SBI Pharmaceuticals Co Ltd
Therapure Biopharma Inc
Tolero Pharmaceuticals Inc
Chemotherapy Induced Anemia - Drug Profiles
(aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epoetin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epoetin zeta biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ferric carboxymaltose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegylated erythropoietin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PHEP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SSS-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TBI-304H - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-0184 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chemotherapy Induced Anemia - Dormant Projects
Chemotherapy Induced Anemia - Discontinued Products
Chemotherapy Induced Anemia - Product Development Milestones
Featured News & Press Releases
Mar 11, 2015: Therapure Innovations Receives FDA Approval to Proceed with a Phase 1 Clinical Trial of Its Novel Anemia Therapeutic TBI 304H
Oct 30, 2012: SBI Pharmaceuticals Submits a Phase-1 Clinical Trial CTA to MHRA for a Drug to Treat Cancer Chemotherapy-induced Anemia
Apr 24, 2012: SBI Pharmaceuticals Announces Obtainment of Marketing Authorization of Products Containing 5-ALA from The Kingdom of Bahrain Ministry of Health
Oct 28, 2011: ALA Study Results Presented at the 49th Annual Meeting of Japan Society of Clinical Oncology
Oct 21, 2011: ALA Study Results Presented at 39th Annual Meeting of Japanese Association for Acute Medicine
Oct 05, 2011: ALA Study Results Presented at Japanese Cancer Association, 70th Annual Meeting
Oct 03, 2011: ALA Study Results Presented at Japanese Society of Parasitology, 71st Meeting
Mar 18, 2011: Announcement of publication of ALA research in International Immunopharmacology
Sep 30, 2010: Safety study for subcutaneous epoetin alfa biosimilar Binocrit/Epoetin alfa Hexal/Abseamed suspended
Dec 01, 2008: International presentation of clinical safety and efficacy data for Binocrit, the worlds first complex biosimilar
Jan 07, 2008: Sandoz and Gambro form strategic alliance
Aug 31, 2007: European Commission approves Sandoz's epoetin alfa Binocrit
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Chemotherapy Induced Anemia, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Chemotherapy Induced Anemia - Pipeline by 3SBio Inc, H2 2017
Chemotherapy Induced Anemia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017
Chemotherapy Induced Anemia - Pipeline by Galenica Ltd, H2 2017
Chemotherapy Induced Anemia - Pipeline by Novartis AG, H2 2017
Chemotherapy Induced Anemia - Pipeline by Panacea Biotec Ltd, H2 2017
Chemotherapy Induced Anemia - Pipeline by Pfizer Inc, H2 2017
Chemotherapy Induced Anemia - Pipeline by PharmaEssentia Corp, H2 2017
Chemotherapy Induced Anemia - Pipeline by PhytoHealth Corp, H2 2017
Chemotherapy Induced Anemia - Pipeline by SBI Pharmaceuticals Co Ltd, H2 2017
Chemotherapy Induced Anemia - Pipeline by Therapure Biopharma Inc, H2 2017
Chemotherapy Induced Anemia - Pipeline by Tolero Pharmaceuticals Inc, H2 2017
Chemotherapy Induced Anemia - Dormant Projects, H2 2017
Chemotherapy Induced Anemia - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Chemotherapy Induced Anemia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *